• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >'Price management' and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.
【24h】

'Price management' and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.

机译：“价格管理”及其对医院药品支出和新西兰医院药品供应的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: In 2002, the Pharmaceutical Management Agency (PHARMAC) began negotiating new price contracts for 90% of hospital pharmaceuticals on behalf of all New Zealand (NZ) public hospitals ("price management"[PM]). The present study was undertaken to examine the impact of 3 years of PM on hospital pharmaceutical expenditure, and the impact of the new contracts on the availability of medicines. METHODS: Annual savings for 29 major public hospitals (financial years 2003/4 to 2005/6) were calculated from the data from 11 hospitals and data from PHARMAC. Inpatient and total hospital pharmaceutical expenditure (IPE, THPE) (2000/1 to 2005/6) were calculated from the data from 23 hospitals. Hospital pharmaceutical expenditure (2000/1 to 2005/6) was compared with community pharmaceutical expenditure (CPE) in NZ, and with THPE in the UK, Canada, Norway, and Sweden. Surveys were undertaken (2004, 2005) to examine any changes in medicine availability resulting from the new contracts. RESULTS: Annual savings were NZDollars 7.84 million (m) to NZDollars 13.45m (2003/4 to 2005/6). Growth in IPE slowed for all hospitals in 2003 to 2004. Mean growth was higher for IPE and THPE than for CPE (8.8%, 9.7% vs. 1.9%). Mean growth in THPE appeared slightly lower in NZ (9.6%) and Norway (7.3%) than in the UK 14%, Sweden 12.5%, or Canada 10.2%. Some availability problems occurred with new contract items ("out-of-stocks"; products perceived as inferior). Problems were usually resolved in weeks, but some took more than a year. CONCLUSION: PM was moderately successful saving NZDollars 8m to NZDollars 13m (6-8%) in 2003/4 to 2005/6 and slowing growth in IPE in 2003/4. Further research should examine whether the favorable economic effects can be sustained while unfavorable effects are minimized.
机译：目标：2002年，药品管理局（PHARMAC）开始代表所有新西兰（NZ）公立医院就90％的医院药品谈判新的价格合同（“价格管理” [PM]）。进行本研究以检查3年的PM对医院药品支出的影响，以及新合同对药品供应的影响。方法：根据11家医院的数据和PHARMAC的数据计算了29家主要公立医院（2003/4至2005/6财政年度）的年度节省。从23家医院的数据中计算出住院患者和医院的药品总支出（IPE，THPE）（2000/1至2005/6）。在新西兰，将医院药品支出（2000/1至2005/6）与社区药品支出（CPE）进行了比较，并将英国，加拿大，挪威和瑞典的THPE与医院药品支出进行了比较。进行了调查（2004年，2005年），以检查新合同导致的药品供应方面的任何变化。结果：每年节省了NZDollars 784万（m）到NZDollars 1345万（2003/4至2005/6）。从2003年到2004年，所有医院的IPE增长都放慢了速度。IPE和THPE的平均增长高于CPE（8.8％，9.7％和1.9％）。新西兰（9.6％）和挪威（7.3％）的THPE平均增长率似乎略低于英国的14％，瑞典的12.5％或加拿大的10.2％。新合同项目（“缺货”;被认为是劣等产品）出现了一些可用性问题。问题通常在几周内即可解决，但有些问题用了一年多的时间。结论：PM在2003/4至2005/6期间成功地将NZDollars 800万节省了NZDollars 1300万（6-8％），并在2003/4中降低了IPE的增长。进一步的研究应研究在将不利影响降至最低的同时，是否可以维持有利的经济影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号